At a glance
| Abbreviation | HRSV |
|---|---|
| ICTV species | Orthopneumovirus hominis |
| Family | Pneumoviridae |
| Baltimore class | V — (−)ssRNA |
| Human infection | Human infection recorded; pattern not classified |
Also called: Orthopneumovirus hominis
Riboviria › Negarnaviricota › Monjiviricetes › Mononegavirales › Pneumoviridae › Orthopneumovirus
What it is
Taxonomy copied from ICTV MSL41.v1 / VMR_MSL41.v1.20260729.xlsx. These ranks are not hand-edited; a correction means re-running the fetch against a newer release.
| Realm | Riboviria |
|---|---|
| Kingdom | Orthornavirae |
| Phylum | Negarnaviricota |
| Class | Monjiviricetes |
| Order | Mononegavirales |
| Family | Pneumoviridae |
| Genus | Orthopneumovirus |
| ICTV identifier | ICTV19750170 |
| NCBI taxon | 3049954 |
| Exemplar isolate | M74568 |
Host evidence
- human: 60,160 GenBank records
Counts of nucleotide records annotated with that host. Evidence of provenance, not a statement of host range.
Where it occurs
Not searched yet. No country-level occurrence data has been curated for this virus. The WHO reported-case data on this site covers a limited set of diseases; a virus outside it gets no map rather than an empty one.
What it does
35
disease-burden figures
8
post-infectious sequelae figures
55
effectiveness estimates
5
vaccine adverse-event figures
28
randomised trial
7
pooled or expert review
20
controlled observational
Deaths per year 2019
101 400 annual number of RSV-attributable deaths
children aged 0-60 months, global (481 studies) per population
quote
We estimated that globally in 2019, there were 33·0 million RSV-associated acute lower respiratory infection episodes (uncertainty range [UR] 25·4-44·6 million), 3·6 million RSV-associated acute lower respiratory infection hospital admissions (2·9-4·6 million), 26 300 RSV-associated acute lower respiratory infection in-hospital deaths (15 100-49 100), and 101 400 RSV-attributable overall deaths (84 500-125 200) in children aged 0-60 months.
Li Y 2022 Lancet
Case-fatality studies published 2000-2019
8.18 pooled case fatality proportion (%)
adults aged 60 years or older, developed countries per case
quote
Among older adults, RSV caused 4.66% (95% CI 3.34-6.48%) of symptomatic respiratory infections in annual studies and 7.80% (95% CI 5.77-10.45%) in seasonal studies; RSV-related case fatality proportion (CFP) was 8.18% (95% CI 5.54-11.94%).
Nguyen-Van-Tam JS 2022 Eur Respir Rev
Lowest and highest vaccine effectiveness reported: 29.4% (Fry SE 2025 JAMA Netw Open; RSV-associated acute respiratory infection, stem cell transplant recipients aged 60-74, adults aged 60-74 years) to 94.6% (Feldman RG 2024 Clin Infect Dis; RSV-related lower respiratory tract disease in adults with at least one cardiorespiratory or endocrine/metabolic condition, adults 60 years or older with at least one coexisting condition of interest). Two of 53 estimates, each from its own study; not a summary figure.
- Randomised trial
- Pooled or expert review
- Controlled observational
What can follow the illness
Guillain-Barre syndrome within 42 days after medically attended RSV disease, adults 65 or older
2.11 incidence rate ratio, risk window vs control window
adults aged 65 years or older, United States; vs the same individuals' control periods (-180 to -22 days and 43 to 180 days from RSV index date)
quote
The adjusted IRR for GBS after RSV disease was 2.11 (95% confidence interval, 1.01-4.37), consistent across sensitivity analyses of alternative risk/control periods and after excluding coinfections.
Liang C 2026 Clin Infect Dis
Current asthma at age 5 years, not infected vs infected with RSV in the first year of life
0.74 adjusted RR for 5-year asthma, uninfected vs infected
5 years, exposure in first year of life, United States (middle Tennessee); vs children infected with RSV during infancy
quote
Not being infected with RSV during infancy was associated with a 26% lower risk of 5-year current asthma than being infected with RSV during infancy (adjusted RR 0·74, 95% CI 0·58-0·94, p=0·014).
Rosas-Salazar C 2023 Lancet
Population attributable fraction of 5-year asthma due to RSV infection in infancy
15 population attributable fraction (%)
5 years, United States (middle Tennessee); vs children not infected with RSV in infancy
quote
The estimated proportion of 5-year current asthma cases that could be prevented by avoiding RSV infection during infancy was 15% (95% CI 2·2-26·8).
Rosas-Salazar C 2023 Lancet
When problems appear: after the infection, and after the vaccine
Two separate clocks on the same logarithmic scale. The first starts at the infection and shows when its sequelae are described as beginning; the second starts at the dose and shows when the vaccine's adverse events are described as beginning. Each bar is one source's printed window, not a synthesis; hover for the source.
- Product label observation window
- Study risk window: when events were counted, not typical onset
Disease risk and vaccine efficacy: every estimate with its population, design and the sentence it came from.
Vaccines
| Name | Developer | Platform | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|---|
| ABRYSVO | Pfizer Inc. | Not searched yet | Routine immunisation | Approved | US: approved | — | candidateId fda-abrysvo (targetDisease 'RSV'); stage copied, not re-de |
| AREXVY | GlaxoSmithKline Biologicals | Not searched yet | Routine immunisation | Approved | US: approved | — | candidateId fda-arexvy (targetDisease 'RSV'); stage copied, not re-der |
| mRESVIA | ModernaTX, Inc. | Not searched yet | Routine immunisation | Approved | US: approved | — | candidateId fda-mresvia (targetDisease 'RSV'); stage copied, not re-de |
| mRNA-1345 (mRESVIA context / next-gen RSV programs) | Moderna | mrna | Routine immunisation | Approved | US: approved | — | candidateId mrna-1345-rsv (targetDisease 'RSV'); stage copied, not re- |
| Respiratory Syncytial Virus Vaccine | See FDA listing | Not searched yet | Routine immunisation | Approved | US: approved | — | candidateId fda-respiratory-syncytial-virus-vaccine (targetDisease 'RS |
| Respiratory Syncytial Virus Vaccine, Adjuvanted | See FDA listing | Not searched yet | Routine immunisation | Approved | US: approved | — | candidateId fda-respiratory-syncytial-virus-vaccine-adjuvanted (target |
In development
| Name | Developer | Platform | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|---|
| Moderna RSV vaccine | Emory University | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT07185399 | candidateId ctgov-moderna-rsv-vaccine-emory-university (targetDisease |
| RSV vaccination (Arexvy, GlaxoSmithKline) | Chinese University of Hong Kong | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT07508644 | candidateId ctgov-rsv-vaccination-arexvy-glaxosmithkline-chinese-unive |
| RSV Vaccine | Canadian Immunization Research Network | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT07097012 | candidateId ctgov-tdap-vaccine-administration-canadian-immunization-re |
| RSVpreF | Pfizer | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT05035212 NCT07653100 NCT07839871 | candidateId ctgov-rsvpref-pfizer (targetDisease 'RSV'); stage copied, |
| RSVpreF (Regimen A) | Pfizer | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT07885956 | candidateId ctgov-rsvpref-regimen-a-pfizer (targetDisease 'RSV'); stag |
| RSVpreF Vaccine | Pfizer | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT07768345 | candidateId ctgov-rsvpref-vaccine-pfizer (targetDisease 'RSV'); stage |
| RSVPreF3 OA investigational vaccine | GlaxoSmithKline | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT04732871 | candidateId ctgov-rsvpref3-oa-investigational-vaccine-glaxosmithkline |
| RSVPreF3 OA vaccine | GlaxoSmithKline | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT07220109 NCT06534892 | candidateId ctgov-rsvpref3-oa-vaccine-glaxosmithkline (targetDisease ' |
| Adjuvanted RSVPreF3 vaccine | GlaxoSmithKline | Not searched yet | Routine immunisation | Phase 2 | Not searched yet | NCT07092865 | candidateId ctgov-adjuvanted-rsvpref3-vaccine-glaxosmithkline (targetD |
| Adjuvanted RZV vaccine | GlaxoSmithKline | Not searched yet | Routine immunisation | Phase 2 | Not searched yet | NCT07712380 | candidateId ctgov-adjuvanted-rzv-vaccine-glaxosmithkline (targetDiseas |
| AZD6489 | AstraZeneca | Not searched yet | Routine immunisation | Phase 2 | Not searched yet | NCT07717840 | candidateId ctgov-azd6489-astrazeneca (targetDisease 'RSV'); stage cop |
| hMPV_Y low dose vaccine | GlaxoSmithKline | Not searched yet | Routine immunisation | Phase 2 | Not searched yet | NCT07628049 | candidateId ctgov-rsv-hmpv-v-low-dose-vaccine-glaxosmithkline (targetD |
| Licensed RSV Vaccine | Sanofi Pasteur, a Sanofi Company | mrna | Routine immunisation | Phase 2 | Not searched yet | NCT06686654 | candidateId ctgov-investigational-hmpv-rsv-vaccine-sanofi-pasteur-a-sa |
| RSV+HMPV vaccine | Sanofi | Not searched yet | Routine immunisation | Phase 2 | Not searched yet | NCT07734649 | candidateId ctgov-rsv-hmpv-vaccine-sanofi (targetDisease 'RSV'); stage |
| Investigational RSV vaccine 1 | GlaxoSmithKline | mrna | Routine immunisation | Phase 1 | Not searched yet | NCT06573281 | candidateId ctgov-investigational-rsv-vaccine-1-glaxosmithkline (targe |
| Low-dose RSV mRNA vaccine | Sinovac Biotech Co., Ltd | mrna | Routine immunisation | Phase 1 | Not searched yet | NCT07418229 | candidateId ctgov-low-dose-rsv-mrna-vaccine-sinovac-biotech-co-ltd (ta |
| mRNA-1345 | ModernaTX, Inc. | mrna | Routine immunisation | Phase 1 | Not searched yet | NCT05743881 | candidateId ctgov-mrna-1345-modernatx-inc (targetDisease 'RSV'); stage |
| mRNA-1365 (Profile 2) | ModernaTX, Inc. | mrna | Routine immunisation | Phase 1 | Not searched yet | NCT07764237 | candidateId ctgov-mrna-1365-profile-2-modernatx-inc (targetDisease 'RS |
| VXB-241 240 mcg | Sanofi | Not searched yet | Routine immunisation | Phase 1 | Not searched yet | NCT06556147 | candidateId ctgov-vxb-241-60-mcg-low-dose-sanofi (targetDisease 'RSV') |
| VXB-251 (RSV/hMPV/PIV3 trivalent vaccine) | Sanofi | Not searched yet | Routine immunisation | Phase 1 | Not searched yet | NCT07295028 | candidateId ctgov-trivalent-rsv-hmpv-piv3-vaccine-candidate-sanofi (ta |
| Ad26/protein preF RSV Vaccine | Janssen Pharmaceutical K.K. | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT05242432 | candidateId ctgov-ad26-protein-pref-rsv-vaccine-janssen-pharmaceutical |
| MVA-BN-RSV | Bavarian Nordic | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT02864628 | candidateId ctgov-mva-bn-rsv-bavarian-nordic (targetDisease 'RSV'); st |
| MVA-BN-RSV vaccine | Bavarian Nordic | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT05238025 | candidateId ctgov-mva-bn-rsv-vaccine-bavarian-nordic (targetDisease 'R |
| RSV MAT | GlaxoSmithKline | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT05229068 NCT04605159 NCT04980391 | candidateId ctgov-rsv-mat-glaxosmithkline (targetDisease 'RSV'); stage |
| RSV preF-based Vaccine | Janssen Vaccines & Prevention B.V. | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT05327816 | candidateId ctgov-rsv-pref-based-vaccine-janssen-vaccines-prevention-b |
| RSV vaccine (GSK3003891A) formulation 1 | GlaxoSmithKline | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT03191383 | candidateId ctgov-rsv-vaccine-gsk3003891a-formulation-1-glaxosmithklin |
Antivirals
Not searched yet. No US-approved antiviral for this virus was found in the openFDA drug label endpoint. Only US labels were searched, and only drugs the FDA classes as antivirals.
Antibodies and immune globulins
| Name | Mechanism | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|
| NirsevimabBEYFORTUS | Not searched yet | Treatment | Approved | US: approved | — | quote1 INDICATIONS AND USAGE BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]; SPL id 7d00fab8-90a7-4e7f-b6d5-e1a7c8bd5933 · verified 2026-10-30 |
Approval status is not a treatment recommendation. Dosing and eligibility are on the label and in national guidelines. This page does not give medical advice and does not render dosing. A development stage is not a measure of how well something works.
Related on this site
- Disease risk and vaccine efficacy — burden figures and trial results, each quoted from its source
- Rsv vaccine — ingredients, schedule and reported side effects
- Vaccine pipeline — candidates listed under “RSV”
- Other Pneumoviridae viruses